middle.news
PYC Therapeutics’ VP-001 Delivers Lasting Vision Gains in RP11 Patients
8:28am on Friday 14th of November, 2025 AEDT
•
Healthcare
Read Story
PYC Therapeutics’ VP-001 Delivers Lasting Vision Gains in RP11 Patients
8:28am on Friday 14th of November, 2025 AEDT
Key Points
VP-001 shows sustained vision improvement in RP11 patients up to 18 months
Treated eyes outperform untreated eyes and natural disease progression controls
No treatment-related serious adverse events reported to date
PYC to meet FDA in Q1 2026 to align on registrational trial design
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Pyc Therapeutics (ASX:PYC)
OPEN ARTICLE